Company: Xilio Therapeutics Inc.
Job title: Director - Translational Biomarkers
XTX301, a half-life extended, tumor-selective IL-12, exerts potent anti-tumor activity in mice and has the potential to widen the therapeutic index of IL-12 treatment. 11:30 am
mXTX301 potently inhibits tumor growth in a syngeneic mouse model. XTX301 is well-tolerated in a repeat dose non-GLP non-human primate study. XTX301 may exert potent anti-tumor activity while widening the potential therapeutic index of IL-12 treatment.Read more
day: Day Two